New Delhi: Global pharma major Lupin Limited (Lupin) today announced the launch of a strategic partnership program aimed at expanding the reach of Precision Sphere, the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi B.V. (Nanomi).

Precision Sphere™ demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent United States Food and Drug Administration’s (U.S. FDA) approval for the first product developed with this platform.

Lupin’s partnership program is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations. Also Read: Lupin plans to build new pharma manufacturing

See Full Page